News and Events
Empowering Communities Through Digital Health: The Techquity by FAITH! Digital Health Advocate Training
Transforming Lives with Digital Health Advocacy The Mayo Clinic’s FAITH! (Fostering African-American Improvement in Total Health) Program, with training support from the Association of Black Cardiologists (ABC), recently completed the second phase of the groundbreaking Techquity by FAITH! initiative. This phase of the Techquity by FAITH! study focused on training Digital Health Advocates (DHAs) to promote cardiovascular health... Read More
Expanding Access to Anti-Obesity Medications
Comments submitted to CMS supporting Medicare coverage of anti-obesity medications and policies that improve access to preventive therapies for patients at risk of cardiovascular disease.
Medicare Coverage for TTVR
ABC provided recommendations to CMS supporting Medicare coverage of transcatheter tricuspid valve replacement while promoting equitable access for patients in rural and underserved communities
Amgen Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study In People With Type 2 Diabetes Living With Obesity or Overweight... Read More
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
– Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes – Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM... Read More
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension – The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early... Read More
Upcoming Events
Don’t Pass on Your Heart Health
October 26 @ 6:00 pm - 8:00 pmRecognizing the Signs, Accelerating Diagnosis, and Improving Patient Care
October 28 @ 7:00 pm - 8:00 pmABC–AHA Joint Symposium: Advancing Quality Care and Equity Through Digital Health, AI and Precision Medicine
November 7 @ 1:30 pm - 2:45 pmABC Membership Update Meeting & Dinner at AHA26
November 7 @ 5:30 pm - 7:30 pm2026 Dr. Walter M. Booker, Sr. Memorial Symposium
November 7 @ 7:30 pm - 9:00 pmSpirit of the Heart Awards Program and Fundraiser | Chicago
October 8, 2027